Subject: to understand practical aspects of using CDR 41/6 Inhibitors in your practice.
Breast cancer in India remained the leading cancer type overall with an estimated incidence of 2.13 lakhs according to PBCR 2022. Among all the subtypes, the HR+, HER 2-ve breast cancer is the major subtype with 50% of the population diagnosed with this subtype.
The HR+, HER 2-ve breast cancer treatment has undergone major changes after the introduction of CDK 4/6 inhibitors. In the HR+, HER 2-ve metastatic breast cancer of CDK 4/6 inhibitors are the current standard of care because of its significant clinical benefit.
Among all CDK 4/6 inhibitors, Palbociclib is the first one to be approved globally and has been in practice for more than 7 years. In India with the recent introductions of several generic versions of Palbociclib has made a significant impact in patient’s affordability and accessibility.
Now since, CDK 4/6 inhibitors are widely used across India it is important to understand various aspects related to their use in HR+, HER 2-ve metastatic breast cancer.
We invite you to participate in this CDK 4/6 inhibitor survey and share relevant clinical information.
We trust you and we are partners in promoting safe and effective medical therapy. In that spirit we hope you will consent to participate in this study. If you do, please sign and return the enclosed reply along with your visiting card for accuracy of records.
|
}}){kind=logo}
}})